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Abstract
Background: Leukocyte infiltration plays an important role in the pathogenesis and progression of myositis, and is
highly associated with disease severity. Currently, there is a lack of: efficacious therapies for myositis; understanding
of the molecular features important for disease pathogenesis; and potential molecular biomarkers for characterizing
inflammatory myopathies to aid in clinical development.
Methods: In this study, we developed a simple model and predicted that 1) leukocyte-specific transcripts
(including both protein-coding transcripts and microRNAs) should be coherently overexpressed in myositis muscle
and 2) the level of over-expression of these transcripts should be correlated with leukocyte infiltration. We applied
this model to assess immune cell infiltration in myositis by examining mRNA and microRNA (miRNA) expression
profiles in muscle biopsies from 31 myositis patients and 5 normal controls.
Results: Several gene signatures, including a leukocyte index, type 1 interferon (IFN), MHC class I, and
immunoglobulin signature, were developed to characterize myositis patients at the molecular level. The leukocyte
index, consisting of genes predominantly associated with immune function, displayed strong concordance with
pathological assessment of immune cell infiltration. This leukocyte index was subsequently utilized to differentiate
transcriptional changes due to leukocyte infiltration from other alterations in myositis muscle. Results from this
differentiation revealed biologically relevant differences in the relationship between the type 1 IFN pathway,
miR-146a, and leukocyte infiltration within various myositis subtypes.
Conclusions: Results indicate that a likely interaction between miR-146a expression and the type 1 IFN pathway is
confounded by the level of leukocyte infiltration into muscle tissue. Although the role of miR-146a in myositis
remains uncertain, our results highlight the potential benefit of deconvoluting the source of transcriptional changes
in myositis muscle or other heterogeneous tissue samples. Taken together, the leukocyte index and other gene
signatures developed in this study may be potential molecular biomarkers to help to further characterize
inflammatory myopathies and aid in clinical development. These hypotheses need to be confirmed in separate and
sufficiently powered clinical trials.
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Myositis is characterized clinically by skeletal muscle weak-
ness and histopathologically by the presence of inflamma-
tory cells in muscle tissue. There are several major
subclasses of myositis, including dermatomyositis (DM),
polymyositis (PM), inclusion body myositis (IBM), and im-
mune mediated necrotizing myopathy (NM). The leukocyte
infiltration present in myositis muscle is believed to con-
tribute to disease pathogenesis [1-5]. The types of immune
cells present in myositis muscle were originally identified in
the 1980s as predominantly CD4+ T cells and B cells in
DM, and CD4+ and CD8+ T cells in IBM [1,6-8], with
more recent identification of plasmacytoid dendritic cells in
DM [9], myeloid dendritic cells in PM and IBM [3], and
plasma cells in all three disorders [2]. Unlike DM, PM or
IBM, NM is characterized by myofiber necrosis associated
with macrophages and minimal T cell infiltration or MHC
Class I expression [10]. Given the differences in clinical
manifestations between these subtypes of myositis and the
lack of optimal efficacious therapies for these diseases,
understanding the molecular characteristics underlying
their subtypes may facilitate the development of novel ther-
apeutics that could benefit patients with myositis.
Technologies such as whole genome microarray have
advanced our understanding of the disease pathogenesis of
myositis [11-13]. A large number of type 1 interferon-
stimulated genes (ISGs) were identified to be strongly over-
expressed in DM muscle and this molecular signature has
been further confirmed by recent studies [4,14]. The activa-
tion of type 1 interferon (IFN) signaling has been observed
in many autoimmune diseases [15,16], such as systemic
lupus erythematosus (SLE) [17-19], systemic sclerosis [20],
rheumatoid arthritis [21], and psoriasis [22]. A type 1 IFN
signature is not only present in DM muscle but also
expressed in DM skin [23], as well as peripheral blood of
DM and PM, reflecting disease activity [24-26]. Based on
the accumulating evidence from recent microarray studies
and other complementary experiments, disease models
have been proposed to emphasize the central role of type 1
IFN pathway activation in the pathogenesis of DM, suggest-
ing that blockade of type 1 IFN might provide clinical bene-
fit to DM patients [27].
In addition to previous studies focused on altered mRNA
expression in myositis, the roles of microRNAs (miRNAs)
in regulating immune responses, muscle development, and
regeneration are also emerging [28-31]. miRNAs including
miR-146a, miR-155, and miR-101 have been shown to be
aberrantly expressed in rheumatic diseases [32-35] and
miR-1, miR-133a/b, and miR-206 have been identified as
muscle-specific miRNAs critical for muscle development
and function [28-31]. Though the role of miRNAs in the
pathogenesis of myositis has yet to be evaluated exten-
sively, it is worth noting that interactions between miRNAs
and type 1 IFN have been identified [36]. Specifically, miR-
146a suppresses the innate immune response not only via
the TLR-mediated NFκB pathway [37], but also negatively
regulates the type 1 IFN pathway in SLE by targeting
STAT1 and IFN regulatory factor 5 (IRF5) [38].
Despite the aforementioned studies, there still lacks a
clear understanding of the disease pathogenesis that under-
lies myositis. Meanwhile, few molecular biomarkers have
been identified to aid in stratifying myositis patients or ob-
jectively quantifying the leukocyte abundance in inflamma-
tory muscle and the corresponding muscle fiber damage.
To address the unmet needs in these areas, we performed
both genome-wide mRNA and miRNA expression profil-
ing in muscle biopsies from myositis patients and normal
controls. Our studies revealed gene expression signatures
specific for myositis and distinct for each subclass of myo-
sitis, as well as multiple pairs of mRNA:miRNA displaying
anti-correlation expression patterns in line with predicted
relationships. Additionally, expression data from this study
indicated that miR-146a displayed a positive correlation
with the type 1 IFN signature rather than the expected
negative correlation in myositis muscle. We postulated that
such positive correlation could be driven by infiltrated
leukocytes; therefore, we developed an invasion model to
account for transcriptional changes due to leukocyte infil-
tration. Further analyses with this invasion model indicated
that the source of ISG expression may differ between sub-
types of myositis, such that in PM and IBM, ISG expres-
sion is associated with infiltrated leukocytes, whereas in
DM, non-leukocyte cells (e.g., muscle cells) might contrib-
ute significantly to ISG expression. Collectively, our results
revealed multiple gene expression signatures that can po-
tentially advance our understanding of the pathologic char-
acteristics of myositis and provide utility as molecular
biomarkers for identifying the right therapeutics for myo-
sitis patients.
Results
Altered mRNA and miRNA expression reveals
upregulation of immune pathways and downregulation
of muscle contraction pathways in myositis
A total of 837 probesets that represent 606 unique genes
were differentially expressed by two-group t-tests in muscle
specimens of myositis patients compared with non-
neuromuscular disease patients (Additional file 1: Table
S1). Most differentially expressed transcripts (88%, 740 of
837) were over-expressed, with only 97 (12%) down-regu-
lated. Functional analysis using IPA (Ingenuity Pathway
Analysis, http://www.ingenuity.com/) and gene set enrich-
ment showed that the most upregulated genes are involved
in the immune and inflammatory responses, including a
large number of ISGs, MHC class I/II proteins, and genes
associated with natural killer cell mediated cytotoxicity. In
contrast, muscle contraction and calcium signaling
pathway-related genes are enriched in the down-regulated
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ively). In addition to the identification of differentially
expressed transcripts in myositis compared to normal con-
trols, we also identified subclass-specific differentially
expressed mRNAs by comparing each myositis subtype to
the normal controls (Additional file 2: Supplementary Text;
Additional file 2: Figure S2; Additional file 3: Table S2).
A similar statistical analysis to determine differentially
expressed mRNAs was applied to miRNA expression
data to identify differentially expressed miRNAs. Of 69
differentially expressed miRNAs identified when com-
paring myositis muscle with normal controls, only five
were over-expressed (miR-146a/b, miR-155, miR-21 and
miR-432). The remaining 64 miRNAs were down-
regulated, including miR-133a/b, miR-1, and miR-29c
(Additional file 4: Table S3). Notably, both miR-146a
and miR-155 are predominantly expressed in leukocytes
and also play important roles in regulating immune
responses [32-35].
Unsupervised hierarchical clustering of the 837 differ-
entially regulated mRNA transcripts revealed two main
transcriptionally-defined subcategories, with all normal
and NM samples clustered within one branch (Figure 1,
branch 1), and all IBM samples clustered within the
other branch (Figure 1, branch 2). DM and PM samples
are divided into both branches. Although unavailable for
the patients within this study, additional information
such as myositis-specific antibodies and other serology
data could have contributed to a more optimal pheno-
typing of the myositis specimens. The lack of these data
may explain some of the heterogeneity observed within
the groups defined strictly by the diagnostic criteria NM,
DM, PM, and IBM. Nevertheless, our results suggest
that specific molecular expression patterns, in addition
to others previously defined for myositis, might provide
insight into classifying and understanding the patho-
physiology of these different subtypes of myositis.
Consensus clustering reveals five gene signatures that
characterize myositis
In addition to identifying molecular expression patterns
specific for myositis as a whole and distinct for its indi-
vidual subtypes, we also applied and merged multiple
clustering algorithms to identify robust clusters of genes
that may provide unique insight into the molecular com-
ponents of myositis (see Methods for the details). To
rule out uninformative genes, we selected the top 200
genes with the most varied expression from the 606 dif-
ferentially expressed genes, among which, only three
were down-regulated. Therefore, we focused on the
remaining 197 up-regulated genes and clustering pro-
duced five clusters with robust gene members (i.e., clus-
ter A-E; Additional file 2: Figure S2C and S3; also see
Methods).
Subsequent functional analyses of the five clusters
revealed that clusters A and B were enriched with type 1
ISGs and immunoglobulins, respectively; clusters C and D
had very similar profiles (Figure 2A) and were enriched
with immune response-related genes (Additional file 5:
Table S4); and cluster E was dominated by MHC class I
genes. These observations led us to define five gene signa-
tures enriched in myositis muscle tissue: type 1 IFN signa-
ture (from cluster A), immunoglobulin signature (from
cluster B), leukocyte I and II indices (derived from clusters
C and D, respectively) and MHC class I signature (from
cluster E). The similarity in cluster results shared by the
different clustering methods confirmed the scientific rigor
of this analysis (Additional file 5: Table S4). We then pro-
ceeded to analyze disease heterogeneity within each myo-
sitis subclass by utilizing these five gene signatures
(Figure 2B-C). In strong agreement with results shown in
Figure 1, NM displayed homogeneous gene signature pro-
files similar to normal muscle, with a slightly elevated
leukocyte II signature observed (see Figure 2B-C). IBM
exhibited clear over-expression of all five gene signatures.
Gene signatures in PM and DM varied from normal-like
signatures to patterns similar to IBM. Most myositis
patients showed coordinate overexpression across all
modules (shown as an equilateral right pentagon in the
radial plot; Figure 2B), but DM showed some hetero-
geneity of relative overexpression of the type 1 IFN
module (i.e., cluster A).
Both leukocyte index I and II are comprised of over-
expressed genes related to immune function (Additional
file 5: Table S4); displayed differences in magnitude be-
tween myositis patients; and are highly correlated with
each other (Spearman rank test; r = 0.97, p < 0.001; see
Figure 2A). Therefore, we selected leukocyte index I
(generated from cluster C) as the leukocyte infiltration
index for subsequent analyses examining altered gene
expression due to increased immune cell infiltration into
muscle.
A leukocyte index distinguishes altered expression of
transcripts due to immune cell infiltration and correlates
with histopathology results
In myositis, leukocyte infiltration and/or clonal expan-
sion results in a marked increase in the abundance of
leukocytes in muscle. Consequently, the interpretation
of gene expression studies in myositis tissue biopsies
can be greatly influenced by immune cell infiltration.
In a principal components analysis of the 837 differ-
entially expressed transcripts in this study, we found
that the first principal component (PC1) accounted
for 75.6% of the variance in the data. PC1 had a sig-
nificant linear association with our proposed
leukocyte index (R
2=0.92, p<0.001), suggesting that
the majority of the overall expression variation was due to
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accounted for by this index. This computational represen-
tation of leukocyte infiltration could eliminate the tran-
scriptional variation generated solely from the increased
immune cell proportion in muscle samples and allow gene
expression changes to be attributed to the appropriate
source.
The ability of the leukocyte index to quantify the extent
of leukocyte infiltration is indirectly supported by the sig-
nificant enrichment of immune response-related tran-
scripts among the differentially expressed transcripts
(hypergeometric test, p< 0.001), as well as the robust clus-
tering of these genes. Additionally, there is a significant
linear correlation between the leukocyte index and
12
Figure 1 Heatmap of 837 differentially expressed transcripts. Transcript expression fold change is represented by the color scale increasing
from blue to white to red; the color key is shown in the top left corner. The 36 subjects are shown horizontally and represented by the color bar
on the top of the heatmap. The color that corresponds to each disease type is displayed in the upper right corner. At the first bifurcation of the
horizontal dendrogram, the subjects are classified into 2 groups from left to right: group 1 and group 2.
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hematoxylin and eosin (H&E) staining (R
2=0.79, p<0.001;
Figure 3). This provides direct evidence to support the
leukocyte infiltration index described here by confirming
that the index accurately reflects leukocyte abundance in
muscle.
In addition to this ability of the leukocyte index to cor-
rectly reflect the abundance of immune cells in muscle
tissue, it may also inversely correlate with the expression
of muscle-specific mRNA or miRNA due to either a
decreased proportion of muscle cells in the sample or
muscle damage. For instance, TTN is a structural
protein abundant in myofibers whose deficiency was
found to be associated with DM perifascicular atrophy
(DM-PFA) [14]; miR-1 is a muscle specific miRNA
[39] that has an important role in muscle develop-
ment [28-31]. Both TTN and miR-1 exhibited a
marked anti-correlation with the leukocyte index
(Spearman rank test; r = −0.70, p<0.001 and r = −0.64,
p<0.001, respectively), providing additional evidence to
support the validity of our invasion model and the
derived leukocyte index.
Multiple mRNAs dysregulated in myositis muscle are not
due to leukocyte infiltration
The development of the leukocyte infiltration index
revealed that most of the over-expressed transcripts in
myositis muscle compared to normal muscle specimens
B A
C 
Cluster A 
Cluster B 
Cluster C 
Cluster D 
Cluster E 
**** 
Figure 2 Gene signatures derived from clusters A-E from the consensus cluster. (A) Pairwise scatter plots of the five gene signatures. The
scatter plots of the signatures of the clusters A-E are displayed in the lower panels, where data points are colored by the sample type (same as
the Figure 1) and red lines represent the lowess (Locally Weighted Scatterplot Smoothing) lines. The corresponding spearman correlation
coefficients are displayed in the upper panels, with significance levels indicated by the stars (*** p < 0.001, ** p < 0.01, * p < 0.05). (B) Subclasses
of myositis characterized by the five gene signatures are shown in the star plots. Each subject is represented with a specific pentagon in the star
plot and the vertices of one pentagon along the spokes (A-E) represent enrichment of the signature scores from clusters A-E. Colors of
pentagons are randomly assigned to distinguish subjects and star plots are grouped by the myositis subclasses. (C) Subjects can be further
characterized by the five gene signatures using a heatmap. The signature scores are represented by the rainbow color in the heatmap, ranging
between 0 (colored in blue) and 4 (colored in red); the color key for each sample’s disease type is displayed horizontally between the sample
identifiers and the heatmap, where, (from left to right), green denotes normal, gray for NM, blue for DM, magenta for PM and red for IBM. The
four DM patients with perifascicular atrophy (PFA) are marked by the star symbol.
Zhu et al. BMC Medical Genomics 2012, 5:53 Page 5 of 12
http://www.biomedcentral.com/1755-8794/5/53were not truly up-regulated due to transcript over-
expression, but rather these expression changes were
actually due to leukocyte cells infiltrating the muscle tis-
sue. Accordingly, we adjusted the expression data matrix
using the infiltration index to identify over-expressed
transcripts unaccounted for by leukocyte infiltration.
Consequently, only 41 (5.5%) out of 740 over-expressed
mRNAs remained over-expressed after adjustment with
the infiltration index (Additional file 6: Table S5). These
miRNAs included many immunoglobulins (IGK, IGH,
IGL), chemokines (CCL8, CCL11, CCL18), myosin com-
plex genes, and cytoskeletal genes (POSTN, TNNT2 and
MYH8). The dramatic reduction of over-expressed tran-
scripts after adjusting for leukocyte infiltration con-
firmed that most of the over-expression is driven by
increased leukocyte abundance in myositis muscle.
Subclass-specific transcript analysis following adjust-
ment for leukocyte infiltration (Additional file 7: Table
S6) revealed that immunoglobulin proteins and some
chemokines were over-expressed in both IBM and PM,
whereas ISGs were heavily over-expressed in DM
muscle. Overall, our results suggested that myofibril and
chemokine signatures exist in DM, PM and IBM, and
likely resulted from changes in gene expression in the
muscle cells themselves rather than alterations due to
leukocyte infiltration. Understanding the contribution of
these pathways altered in muscle tissue may provide
keen insight into the pathogenesis of specific subclasses
of myositis.
The leukocyte index and the type 1 IFN signature in
myositis muscle
After re-assessing gene expression changes to account for
leukocyte infiltration, we observed that ISGs remained
highly over-expressed in muscle biopsies particularly from
DM patients. Accordingly, we investigated the relation-
ship between over-expression of ISGs and the leukocyte
index in more depth. Strikingly, the type 1 IFN signature
showed a significant linear correlation with the leukocyte
index with exception of four outliers (i.e., the DM sub-
jects GEIM 12, 272, 382 and 383; see Figure 4). The linear
correlation suggests that leukocyte infiltration might have
a more pronounced effect on ISG over-expression in IBM,
PM, and DM without perifascicular atrophy (PFA; see
Table 1); whereas in a subset of DM patients with
marked ISG over-expression, especially those with PFA,
other cell types (e.g., muscle fiber cells) might contribute
to type 1 IFN pathway activation.
Observations that a correlation between ISG over-
expression and leukocyte infiltration varied between myo-
sitis subtypes prompted us to also investigate the correl-
ation of miR-146a with the leukocyte index as this
miRNA has been previously reported to negatively regu-
late the type 1 IFN pathway in SLE [38]. Our results indi-
cated that both miR-146a and the type 1 IFN signature
display an overall positive correlation with the leukocyte
index (Spearman rank test; r =0 . 6 4 ,p <0 . 0 0 1 ;r =0 . 7 2 ,
p < 0.001, respectively; also see Figure 4), and therefore
they are likely to be positively correlated with each other
Figure 3 Correlation between leukocyte infiltration index and
H&E staining. A significant linear correlation is displayed in the
scatter plot between the leukocyte infiltration index and the degree
of inflammation assessed by H&E staining (0=no inflammation,
1=sparse inflammation, 2=mild inflammation, 3=moderate
inflammation, and 4=severe inflammation). Data points are colored
by the sample type; color key is displayed in the upper right corner
of the plot. The regression line is denoted by the blue dotted line
(intercept=0.07, slope=1.00; R
2=0.79, p<0.001).
Figure 4 Correlation between type 1 IFN signature score and
leukocyte infiltration index in myositis. A significant linear
correlation is displayed in the scatter plot between type 1 IFN index
and leukocyte infiltration index. Data points are colored by the
sample type; color key is displayed in the upper right corner of the
plot. The regression line (R
2=0.41, p<0.001) is denoted by the black
dotted line and 95% confidence interval is outlined by the red
dotted line and gray shaded background. The subject identifiers of
the four outliers are labeled. When excluding the four outliers, the
R-squared value in the regression analysis escalates from 0.41 to 0.91.
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sociation was evident primarily in IBM and PM (Figure 5),
where leukocyte infiltration may be responsible for the
observed alterations in miR-146a expression. In contrast,
6 out of 8 DM samples displayed a negative pattern of as-
sociation between the expression level of miR-146a and
the type 1 IFN signature, similar to what has been shown
previously in SLE [38].
To examine the possibility that miR-146a could nega-
tively regulate the type 1 IFN signature in muscle tissue,
we utilized an in vitro muscle cell model. The level of
miR-146a expression was altered in C2C12 muscle cells
by transfecting either miR-146a mimics or miR-146a
inhibitors into this cell line prior to stimulation with
type 1 IFN. Measuring the resulting expression levels of
ISGs illustrated that miR-146a is able to negatively
Table 1 Patient information
Subject ID Age Gender Disease type* Muscle Disease duration (months) Treatments
GEIM12 74 F DM Biceps 1 None
GEIM54 62 M PM Quadriceps 24 None
GEIM57 38 F Normal Biceps N/A N/A
GEIM63 37 F Normal Biceps N/A N/A
GEIM64 77 M NM Biceps 6 Pred
GEIM90 90 M PM Deltoid 3 None
GEIM96 86 F PM Biceps 3 None
GEIM127 68 F IBM Biceps 36 Azathioprine
GEIM133 60 F Normal Quadriceps N/A N/A
GEIM174 36 F PM Biceps 3 None
GEIM272 25 F DM (with PFA) Biceps 3 Pred x 4 days
GEIM306 64 F NM Biceps 17 Pred
GEIM312 76 F PM Biceps 96 None
GEIM315 39 F DM Biceps 3 None
GEIM322 58 F PM Biceps 180 None
GEIM331 87 F PM Deltoid 36 Pred
GEIM335 71 F IBM Quadriceps 24 None
GEIM340 83 F NM Biceps 66 Pred
GEIM349 28 F DM Biceps 18 Pred, Azathioprine
GEIM354 76 M IBM Biceps 60 None
GEIM363 79 F IBM Biceps 36 None
GEIM365 41 M Normal Biceps N/A N/A
GEIM368 61 F Normal Quadriceps N/A N/A
GEIM372 61 M IBM Quadriceps 84 Dexamethasone taper
GEIM373 80 F IBM Quadriceps 90 None
GEIM374 47 F IBM Quadriceps 54 None
GEIM375 50 F NM Quadriceps 6 None
GEIM376 37 M DM Deltoid 4 None
GEIM377 50 M IBM Biceps 24 None
GEIM380 61 M IBM Quadriceps 24 None
GEIM382 30 F DM (with PFA) Deltoid 1 None
GEIM383 44 F DM (with PFA) Deltoid 2 Pred x 1 month
GEIM385 61 F PM Biceps 60 Etancercept
GEIM389 40 M DM (with PFA) Biceps 5 N/A
GEIM391 71 M NM Quadriceps 7 None
GEIM397 77 M IBM Biceps 84 None
* DM, dermatomyosits; PM, polymyositis; IBM, inclusion body myositis; PFA, perifascicular atrophy.
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(Figure 6), as demonstrated by the increased ISG expres-
sion following inhibition of miR-146a and the decreased
ISG expression following increased miR-146a levels.
These trends and degree of effect on ISGs by miR-146a
are in agreement with what has been reported previously
in SLE [38], and suggest a possible role for miR-146a in
regulating the type 1 IFN pathway in muscle, although
this remains to be verified by in vivo studies.
Discussion
Most biological tissue specimens are heterogeneous, often
consisting of multiple cell types. This heterogeneity is evi-
dent in myositis muscle biopsies and confounds transcrip-
tional analyses, as the source of an observed expression
change is unclear. We developed a leukocyte index to dif-
ferentiate the transcriptional alterations due to an increased
proportion of inflammatory cells from other changes at the
expression level. The positive correlation of this computa-
tional leukocyte index with immune cell infiltration scored
from H&E staining and the expression of lymphocyte-
specific mRNAs/miRNAs validated our invasion model and
further confirmed the use of this index as a surrogate for
leukocyte abundance in muscle. The ability to distinguish
between muscle-derived transcripts and genes over-
expressed due to leukocyte infiltration may improve the
interpretation of gene expression results and increase exist-
ing knowledge of molecular pathways critical for myositis.
In addition to the leukocyte index, we have also identi-
fied several other gene signatures (each from a consen-
sus cluster with coherently expressed gene members):
MHC class I, type 1 IFN, and immunoglobulin signa-
tures. The type 1 IFN, MHC class I, and immunoglobu-
lin signatures have been reported previously in various
subclasses of myositis, in good agreement with the
results in this study. Also, the current study is the first
to systematically evaluate these genomic signatures to-
gether, which could provide important insight into the
pathogenesis and potential therapeutic targets for myo-
sitis. Several transcripts displaying a good correlation
with the leukocyte index and/or the type 1 IFN signature
in muscle were also identified in this study, such as
TTN, miR-1, miR-155 and amyloid beta (A4) precursor
protein-binding, member B and member 1 interacting
protein (APBB1IP). However, the small sample size and
insufficient clinical information preclude us from evalu-
ating the association of these molecular characteristics
with the disease activity/severity within this study. Add-
itionally, there was not adequate material to conduct
extensive immunohistochemistry studies on patients in
this study to correlate the presence of immunoglobulin
and MHC class I protein levels with the corresponding
gene signature scores. Continued effort to evaluate these
molecular features in clinical studies where detailed clin-
ical/demographic information is available will allow for
further characterization of the utility of these potential
biomarkers to aid in the patient stratification or to pre-
dict therapeutic efficacy.
In contrast to the positive correlation identified be-
tween the type 1 IFN signature and leukocyte infiltration
index in PM and IBM, a positive association was not
observed in most DM samples. One possible explanation
is that the type 1 IFN signature in PM and IBM is
mainly driven by leukocyte infiltration into muscle, while
distinct drivers might be present in DM. Our results
support the previous finding [14] that the type 1 IFN sig-
nature in DM might be connected with PFA (Figure 4),
although a larger sample size is desired. Notably, this
association between PFA and the type 1 IFN signa-
ture was also accompanied by the presence of the
MHC class I signature (see Figure 2B, C). Additional
studies need to be carried out in the future to confirm
these observations.
The ability to distinguish the role of different cell types
at disease sites is important in identifying anti-correlations
between miRNA and mRNA expression, such as the ex-
pression of miR-29c and collagen genes (Additional file 2:
Supplementary Text and Supplementary Methods) and
other anti-correlations that may be important to the patho-
genesis of myositis. Anti-correlations comparing mRNA
Figure 5 Intricate association between the expression of miR-
146a and type 1 IFN signature score in a subclass of myositis.
Data points are colored by the sample type in this scatter plot; color
key is displayed in the upper right corner of the plot. The identity
reference line y=x is denoted by the blue dotted line. Type 1 IFN
signature displays a positive pattern of association in most subjects
including the normal control, NM, PM, IBM and some DM, as
highlighted in the light blue shaded oval. On the other hand, the
type 1 IFN signature displays a negative pattern of association with
the expression level of miR-146a in most DM (highlighted in the
pink shaded oval). The subject identifiers of the eight DM subjects
are all labeled in this plot.
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the effect of increased leukocyte cell abundance, potentially
masking true correlations between mRNAs/miRNAs in
various disease settings. The positive correlation identified
between miR-146a and the type 1 IFN signature in PM
and IBM is one example where the increased number of
leukocytes in muscle influenced the resulting gene expres-
sion comparison between myositis patients and normal
subjects. Taken together, these results strongly support the
application of the leukocyte infiltration index to transcrip-
tomic studies to appropriately characterize altered mRNA
and/or miRNA expression from heterogeneous biological
samples, thus allowing for more meaningful interpretation
of microarray data with the aim of increasing our under-
standing of the fundamental mechanisms of disease
pathogenesis.
Evaluation of the effect of miR-146a in the suppression
of the type 1 IFN pathway in myositis muscle revealed
an interaction that was confounded by leukocyte infiltra-
tion. Nevertheless, our results indicated that a subset of
DM patients had high type 1 IFN signatures and low
miR-146a expression in muscle. Additional in vitro
results showed that altered miR-146a levels in muscle
cells could regulate the activation of the type 1 IFN
pathway. Due to the small number of myositis samples
displaying an anti-correlation between miR-146a and the
type 1 IFN pathway and the lack of in vivo studies
confirming this relationship, the exact functional role of
miR-146a in myositis remains uncertain. However, con-
tinued work on characterizing this relationship in myo-
sitis is warranted.
Conclusions
In this study comparing transcriptional changes between
myositis muscle biopsies and normal controls, we identi-
fied several gene signatures, including a leukocyte index
and a type 1 IFN signature, as genomic biomarkers to
characterize myositis subjects at the molecular level.
Additionally, use of the leukocyte index to account for
transcriptional changes due to increased lymphocyte in-
filtration into muscle revealed that the majority of these
changes are driven by increased leukocyte abundance.
Investigation into the relationship between leukocyte in-
filtration and a type 1 IFN signature suggested that
increased ISGs might have two distinct sources at the
myositis disease site: one is closely associated with
leukocyte infiltration in IBM, PM and some DM; and
the other source is not certain, but may be due to MHC
class I-expressing myofibers, especially in some DM
patients. Further understanding of the relationship be-
tween these signatures in vivo, as well as any association
with myositis disease severity or activity will be explored
in future clinical studies to evaluate their utilities as bio-
markers. The ability to differentiate the transcriptional
Figure 6 miR-146a alters the expression of type 1 IFN inducible genes in C2C12 muscle cells. C2C12 cells were transfected with miR-146a
mimics and miR-146a inhibitors, as well as the appropriate scrambled controls. 24 hours after transfection, cells were stimulated with mouse IFN-
alpha for 4 hours before RNA was isolated and profiled for alterations in ISGs. Regulation of the IFN pathway was demonstrated by increased ISG
transcript levels following inhibition of miR-146a, as well as decreased ISG transcript levels following addition of miR-146a. Values are shown as
mean ± SEM and represent results from 3 independent experiments.
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tory cells from other changes at the expression level
increases our ability to connect changes in specific cellu-
lar subsets with important biological phenomena critical
for disease development or progression.
Methods
Patients and tissue samples
Muscle samples from 36 patients (5 normal controls,
5 NM, 8 DM, 8 PM and 10 IBM) were studied (Table 1).
Normal controls are those subjects who were not sus-
pected clinically to have neuromuscular disease; had
normal muscle strength by examination; and showed
normal serum CK levels. Diagnostic criteria for IBM,
DM, and PM were as previously described [11]. Patients
with NM had an acute or subacute myopathy responsive
to immunotherapy, with pathology showing necrotic
muscle fibers without inflammatory cells other than
macrophages. Myositis-specific antibodies may also be
highly predictive of the clinical pheno-subtype of myo-
sitis; however, these data were not available for the
patients utilized in this study and could not be incorpo-
rated into the overall phenotyping of the samples.
Open muscle biopsies were performed at the time of a
diagnostic biopsy (the biopsy site is listed in Table 1)
and immediately frozen in liquid nitrogen for RNA and
miRNA. A separate piece of muscle was used for
hematoxylin and eosin (H&E) staining. Patients provided
informed consent for research and institutional review
boards approved all studies.
Hematoxylin and eosin (H&E) staining and assessment
H&E stained frozen sections were examined microscopic-
ally by a single examiner blinded to diagnosis. The degree
of inflammation graded between 0–4 (0=no inflammation,
1=sparse inflammation, 2=mild inflammation, 3=moderate
inflammation, and 4=severe inflammation).
Total RNA extraction
miRNA-RNA was extracted from muscle biopsies using the
mirVana miRNA Isolation kit (Applied Biosystems/Ambion,
Austin, TX), according to manufacturer’si n s t r u c t i o n s .
mRNA profiling by Affymetrix microarray
Small species RNAs (e.g. miRNA, snRNA, tRNA) were
removed from a volume of each miRNA-RNA sample
using Agencourt RNAclean magnetic beads (Beckman-
Coulter, Brea, CA). The resulting total RNA was profiled
using Affymetrix Human Genome U133 plus 2.0 Gene-
Chips
W (Affymetrix, Santa Clara, CA). A selection of
genes with high expression intensities identified by
microarray were validated by quantitative Real-Time
PCR (Additional file 2: Supplementary Methods;
Additional file 2: Figure S4).
miRNA profiling by ABI TaqMan Low-Density Array (TLDA)
miRNAs were profiled using TLDA microRNA Cards v1.0
(Applied Biosystems, Foster City, CA). Single-stranded
cDNA synthesis from 100 ng of total miRNA-RNA and
pre-amplification of specific miRNA targets was performed
according to the manufacturer’s protocol. The microRNA
cards were loaded and run on an Applied Biosystems
7900HT Real-Time PCR system.
Normalization of microarray and TLDA expression data
Probe-level summaries of microarray expression data were
calculated using fRMA, which was implemented in R
Bioconductor (http://bioconductor.org). The microarray
expression data and the normalized expression data matrix
were deposited at the NCBI Gene Expression Omnibus
(accession number GSE39454). For quantitative RT-PCR,
data analysis of Ct values was conducted with SDS v2.2.2
software (Applied Biosystems). All samples were normal-
ized to the mean Ct value of the endogenous control tran-
script RNU48.
Statistical analysis
All statistical analyses were performed using R (http://
www.r-project.org). Two group t-test was applied to
identify differentially expressed mRNA/miRNAs in myo-
sitis muscle biopsies compared to the normal controls.
The empirical Bayes method (from Bioconductor limma
package) was also employed to identify myositis
subclass-specific expression patterns [37]. In both of the
overall and subclass-specific comparisons, the transcripts
with average fold change > 4 and adjusted p-value for
Benjamini-Hochberg < 0.05 are considered significant.
Invasion model
Measurements of gene expression from heterogeneous
samples are typically confounded by the abundance of
the constituent cell types, which generally can be formu-
lated as a linear model. In this study, we considered a
special case of the linear model, where the proportion of
a certain subset t of cell types increases significantly in a
certain condition (e.g., the disease state) compared to a
normal condition. We named this model the invasion
model. On the basis of some simple interpolation (see
Additional file 2: Supplementary Methods for details),
the invasion model characterizes several valuable out-
comes when the special case holds: 1) variations of the
gene expression will result predominantly from the
alterations in proportions of the cell type t; 2) the t cell
type-specific gene will be co-overexpressed even if there
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sion; 3) the average of the fold changes of the t cell type-
specific gene expression is a good indicator of the
increase in the fraction of the cell type t in a state change,
for example, from the normal state to a disease state. The
portions of invading cell types (or subsets) may change in
distinct patterns and thus multiple cell type-specific gene
signatures will be identified in that case.
The invasion model can be readily applied to myositis to
assess the leukocyte infiltration into the disease site. Abun-
dance of leukocytes is low in normal skeletal muscles and
m a yi n c r e a s ed r a m a t i c a l l yi n inflammatory myopathies.
Given the existence of some mRNAs and/or miRNAs pre-
dominantly expressed in leukocytes, we should observe
strong concordance among the overexpression of those
particular protein-coding and/or non-protein coding tran-
scripts. In practice, constant expression of those transcripts
is not a requisite in the invasion model as long as the vari-
ation of the expression is minor relative to the variation of
the lymphocyte cell abundance due to the infiltration,
according to the equation (5) in Additional file 2: Supple-
mentary Methods. It is anticipated that the leukocyte-
specific transcripts should display “coherent” overexpression
compared to the normal muscle biopsies and form one or
more large clusters. As a result, the overexpression of those
mRNA/miRNAs could serve as a gene signature to quantify
the level of the infiltration of one or multiple subtypes of
dominant leukocytes in myositis muscle.
Consensus clustering and gene signatures
A consensus clustering approach was employed to deter-
mine the proper cluster numbers and the robust mem-
bers within each cluster by using R clusterCons package
[40]. Multiple clustering algorithms (including agglom-
erative nesting clustering (agnes), divisive analysis clus-
tering (diana), k-means, partitioning around medoids
(pam), and hierarchical clustering (hclust)) were applied
with a bootstrapping approach. The clustering results
were further merged to identify the consensus clusters
and their robust members. The membership robustness
of each gene ranged from 0 to 1, defined as the average
connectivity between a gene and all other members of
the cluster [40]. Thus, a robust member, by definition,
should have a high score (i.e., close to 1). We empirically
used 0.6 as the cutoff value of membership robustness
and took any cluster with at least five robust members
to define the gene signature. For each cluster, a gene sig-
nature was defined as the median of the fold changes of
the robust members relative to the normal controls.
To reduce the scale of the clustering problem and ex-
clude uninformative genes, we applied the clustering
only on a subset (i.e., ~200) of the differentially
expressed genes that had the highest expression variance
across subjects as recommended by the clusterCons
developers [40].
Functional analysis of differentially expressed mRNAs
The differentially expressed transcripts are annotated in
multiple ways: Ingenuity Pathway Analysis Tool (IPA;
Redwood City, CA), hypergeometric enrichment of gene
ontology (GO) terms, KEGG pathways (using Biocon-
ductor GOstats package) and the gene sets from
MSigDB (Molecular Signatures Database, http://www.
broadinstitute.org/gsea/msigdb/index.jsp). IPA micro-
RNA Target Filter is also utilized to explore the likely
interaction between differentially expressed mRNAs and
miRNAs (see Additional file 2: Supplementary Methods;
Additional file 8: Table S7).
C2C12 cell maintenance and transfection
C2C12 cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA) and cultivated in
recommended media at 37°C in a humidified atmosphere
with 5% CO2. Artificial miR-146a mimics (Dharmacon)
and miR-146a inhibitors (Dharmacon), as well as the
appropriate scrambled controls, were transfected into
C2C12 cells with PrimeFect siRNA (Lonza) according to
manufacturer’s protocol. 24 hours after transfection, cells
were stimulated with mouse IFN-alpha (PBL interferon
source) for 4 hours before RNA was isolated and profiled
for alterations in IFN-inducible genes.
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